Candida Albicans News and Research

RSS

IRIC scientists identify vitamin B3 as potential antifungal treatment

A team of scientists from the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal have identified vitamin B3 as a potential antifungal treatment. Led by IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre Thibault, in collaboration with Alaka Mullick, from the Biotechnology Research Institute of the National Research Council Canada, the study is the subject of a recent article in Nature Medicine.

9 Jul 2010

Breathing system filters used in anaesthesia allow passage of bacterial, yeast infections

Doctors have highlighted potential problems with the breathing system filters used in anaesthesia, including intensive care units, after demonstrating that they don't provide protection from harmful bacteria and yeast when they become wet.

6 Jul 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Yeast produce a hormone that triggers fungal cells to become more infectious

In their ongoing studies of how yeast (fungi) can infect a host and cause disease, a research team at the Life Sciences and Bioengineering Center at Worcester Polytechnic Institute (WPI) has made an unexpected discovery. They found that yeast produce a hormone previously known to be made by plants, and that the presence of that hormone in sufficient quantity within the yeast's immediate environment triggers the fungal cells to become more infectious.

29 May 2010

Study could provide new strategies to prevent hospital-acquired infections

A bacterial pathogen can communicate with yeast to block the development of drug-resistant yeast infections, say Irish scientists writing in the May issue of Microbiology. The research could be a step towards new strategies to prevent hospital-acquired infections associated with medical implants.

3 May 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Rituximab treatment reduces patients' response to pneumonia vaccine

Researchers from Johns Hopkins University determined that immune responses to the tetanus vaccine were not changed when rituximab in combination with methotrexate (MTX) was compared with MTX alone in patients with rheumatoid arthritis (RA).

7 Jan 2010

American Biotech Labs' ASAP Antibacterial Silver Gel receives FDA 510(k) medical device clearance

American Biotech Labs, LLC (ABL), developer of a new class of products based on the company's patented nano-catalytic SilverSol Technology(R), today announced that the company has obtained clearance by the U.S. Food and Drug Administration (FDA) to market its ASAP Antibacterial Silver Wound Dressing Gel as a prescription 510(k) medical device throughout the United States. Clifton Mining Company is a major shareholder in American Biotech Labs.

17 Nov 2009

Antibiotic effects of pumpkin may help fight yeast infections

The skin of that pumpkin you carve into a Jack-o'-Lantern to scare away ghosts and goblins on Halloween contains a substance that could put a scare into microbes that cause millions of cases of yeast infections in adults and infants each year.

29 Oct 2009

Propolis exhibits antioxidant and anti-microbial properties that are beneficial to human health

Growing concerns about health has caused the scientific community to focus their interest on investigating functional foods which contribute to boosting the prevention and reduction of the risk of suffering from certain illnesses. The benefits of this product lies in its composition and, thus, its study, identification and subsequent extraction provides a useful tool which enables making high added-value products, given their high concentration of biologically active compounds.

28 Oct 2009

Preachers Coffee signs agreement to enhance its nutraceutical-health marketing strategy

PREACHERS COFFEE, INC. (PINKSHEETS: PRCF) in order to enhance its Nutraceutical Health Marketing Strategy entered into an Agreement with "GANO EXCEL COFFEE COMPANY" -- a robust Multi Level Marketing Health Coffee Company that has a broad range of 3,000,000 customers with respect to population and followings.

23 Oct 2009

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

15 Sep 2009

Microbe's multilayer defence mechanisms could treat fungal infections

Unravelling a microbe's multilayer defence mechanisms could lead to effective new treatments for potentially lethal fungal infections in cancer patients and others whose natural immunity is weakened.

8 Sep 2009

Same-sex mating found in most common human fungal pathogen Candida albicans

Brown University researchers have discovered that Candida albicans, a human fungal pathogen that causes thrush and other diseases, pursues same-sex mating in addition to conventional opposite-sex mating.

12 Aug 2009

Tamoxifen kills fungus cells and may prevent them from causing disease

An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born prematurely and patients with cancer. Some scientists suspected that tamoxifen has antifungal properties; now new research from the University of Rochester Medical Center shows that it actually kills fungus cells and stops them from causing disease.

20 Jul 2009